Ois Podcast

Harrow isn’t a household name (yet), but eye care professionals have trusted its products for over a decade.The Nashville-based company produces Dexycu, an intraocular steroid; Iopidine for intraocular pressure control; and most recently, five Novartis products that Harrow acquired in December 2022.Rob Rothman, MD, caught up with Harrow founder and CEO Mark Baum to find out how he grew the company from worse than nothing—he acquired, restructured, and reorganized a company in bankruptcy in 2011—to a publicly traded organization with an enterprise value of $750 million.Baum describes Harrow as a “consortium of entrepreneurs.” That consortium includes:Eton Pharmaceuticals, developing products to treat rare diseaseSurface Ophthalmics, developing preservative-free products to treat dry eye disease and post-operative painMelt Pharmaceuticals, which produces MKO Melt, an FDA-approved analgesicHarrow built its business off compounded medications. By meeting needs of physicians in that way, it grew from zero to over